E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

Overview of attention for article published in Journal of Clinical Oncology, August 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 1 news outlet
twitter: 33 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 137 Mendeley

So far, Altmetric has seen 50 X posts from 33 X users, with an upper bound of 355,173 followers.

RT @RoisinMConnolly: E2112 trial @eaonc had co-primary endpoints PFS/OS and did not meet, in N American 🇺🇸 cohort. In my opinion, larger PF…

RT @tmprowell: #SABCS21 #bcsm Dr. Binghe Xu presents positive superiority trial of RCT of exemestane + entinostat/placebo. Control arm PFS…

E2112 trial @eaonc had co-primary endpoints PFS/OS and did not meet, in N American 🇺🇸 cohort. In my opinion, larger PFS difference & true OS benefit, minimal toxicity, are most ideal when considering new therapies for #MBC. Much more work to do! #SABC…

RT @tmprowell: #SABCS21 #bcsm Dr. Binghe Xu presents positive superiority trial of RCT of exemestane + entinostat/placebo. Control arm PFS…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 46 additional X posts.